Living Homeopathy International, which sells homeopathic products in Hong Kong, filed on Friday with the SEC to raise up to $6 million in an initial public offering.
The Hong Kong, China-based company plans to raise $6 million by offering 1.3 million shares at a price range of $4 to $6. At the midpoint of the proposed range, Living Homeopathy International would command a market value of $56 million.
Living Homeopath International offers healthcare products, including homeopathic remedies (9% of FY24 revenue), homeopathic co-remedies (80%), and flower remedies (4%), which it primarily acquires from manufacturers and resells under its LIVING brand; as well as personal care (2%; e.g. mouthwash, toothpaste, shampoo) and water filter products (4%), which it develops and works with manufacturers to produce. According to Frost & Sullivan, the company had a leading 41% market share of homeopathic product in Hong Kong in 2023.
The Hong Kong, China-based company was founded in 1994 and booked $8 million in sales for the 12 months ended September 30, 2024. It plans to list on the Nasdaq under the symbol LHI. Living Homeopathy International filed confidentially on November 1, 2024. US Tiger Securities is the sole bookrunner on the deal. No pricing terms were disclosed.
